# Beamion LUNG-2 (NCT06151574)

> Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

No report yet. It can be ordered.

- Drugs tested: zongertinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06151574
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Lung Cancer, Non-squamous, Non-small Cell
- Interventions: zongertinib; pembrolizumab; cisplatin; carboplatin; pemetrexed
- Enrollment: 428
- Primary outcome: Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review

## Indexed commentary on Beamion LUNG-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- Podcasts: 3
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=beamion-lung-2-nct06151574

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06151574", "email": "<work email>"}; the inbox owner confirms by the emailed link.